Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN BLADDER)

NCT02710734 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.

NCT NCT02710734
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02710734 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN BLADDER)
Lead sponsor
Fox Chase Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
February 24, 2016
Completion date
December 31, 2025
Enrollment
78 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

urothelial carcinoma of the bladder